Celltech looks a real tonic

INVESTORS attracted by the potential in the biotechnology industry but worried about the risks should look at Celltech. The group has excellent management and a broadly based pipeline of potential new drugs which could yield blockbuster returns. It is not over-dependent on any single project. At the same time it has plenty of cash in the balance sheet, a profitable and dramatically expanding manufacturing business, and alliances with established industry giants which ensure that it is at no risk of running out of money for the foreseeable future.

Rivals are increasingly taking note of Celltech as a model of how a biotechnology company should be managed in the 1990s. In the United States, by contrast, many smaller biotech companies have funding problems. This changing perception has been reflected in a share price up from 219p, when I wrote about the group last year, to 286p currently, against a flotation price of 250p in December 1993.

Investors should not be put off by the rise that has already taken place. Despite the cautious approach, Celltech is playing for high stakes and the bull market in the shares may have only just begun. Fair-value models for 1997, making the admittedly considerable assumption that there are no great disappointments in clinical trials between now and then, could see the shares worth more than £l0, even though the group is unlikely to be seriously profitable much before the end of the decade.

One factor in the transformation of Celltech's prospects is a new management team. Dr Peter Fellner and Dr David Bloxham, respectively group chief executive and chief executive of Celltech Therapeutics (the drug development arm), both ex-Roche, were brought in to give the group focus. They have transformed it. But the real pay-off will come as we approach the 10- year anniversary of their arrival, when we will know if any of the trial drugs is a winner.

The next couple of years could be crucial. The group has two particularly promising compounds: CDP 571 for the treatment of rheumatoid arthritis, inflammatory bowel disease and septic shock; and CDP 840 for the treatment of asthma. Some idea of how seriously these compounds are taken in the industry comes from the partnerships Celltech has formed to develop them. Bayer is committed to make payments (known as milestone payments) to the group of £29m to fund the development of CDP 571. Milestone payments of up to £31.5m, payable over a five-year period, have been committed by Merck on CDP 840. The group has alliances with four large companies with milestone payments of £62m in total, of which £l3.6m has been paid so far. The deal is that Celltech does the initial research. The huge cost of further development and marketing is then handled by the companies. Yet Celltech can still expect a share of between 25 and 45 per cent of the profits on its products.

A common element in all Celltech's compounds is their relation to human monoclonal antibodies and the immune response. In effect, the group, with a research staff of 185 based in Slough, has become a world-recognised centre of excellence. This has other benefits. First, the group is a leading manufacturer of antibodies for its own and other companies' use. Last year this division made profits of £2m on £l4.2m of sales, despite considerable disruption at the factory. Profits are also understated by up to £2m because much of the production is supplied at cost within the group. Expansion is under way in both this country and New Hampshire in the US. Profits from this division could be £5m to £l0m by the end of the decade.

A worldwide surge of interest in the therapeutic use of antibodies could also generate royalties for the group, because many companies will be using Celltech's technology. First fruits are being seen with a new drug launched by Eli Lilly, which could generate royalties for the group of more than $5m (£3m) in a few years if sales reach $250m. An educated guess is that as other human antibody-based compounds come on stream, sales could reach $lbn, generating perhaps $20m of annual profit for Celltech.

Celltech's current market capitalisation of £203m could be justified by its human antibody manufacturing and licensing income, even if none of its third- party-funded drug development programmes is successful. Yet prospects look good or the big drug companies would not be providing such chunky payments. If just one of these drugs is a winner the rewards could be spectacular. The shares look an attractive speculative play with far less downside than is usual with biotechnology investments.

Start your day with The Independent, sign up for daily news emails
Ben Little, right, is a Labour supporter while Jonathan Rogers supports the Green Party
general election 2015
The 91st Hakone Ekiden Qualifier at Showa Kinen Park, Tokyo, 2014
Life and Style
Former helicopter pilot Major Tim Peake will become the first UK astronaut in space for over 20 years
food + drinkNothing but the best for British astronaut as chef Heston Blumenthal cooks up his rations
Kim Wilde began gardening in the 1990s when she moved to the countryside
peopleThe singer is leading an appeal for the charity Thrive, which uses the therapy of horticulture
Alexis Sanchez celebrates scoring a second for Arsenal against Reading
Life and Style
An easy-peel potato; Dave Hax has come up with an ingenious method in food preparation
voicesDave Hax's domestic tips are reminiscent of George Orwell's tea routine. The world might need revolution, but we like to sweat the small stuff, says DJ Taylor
Japan's population is projected to fall dramatically in the next 50 years (Wikimedia)
Life and Style
Buyers of secondhand cars are searching out shades last seen in cop show ‘The Sweeney’
motoringFlares and flounce are back on catwalks but a revival in ’70s car paintjobs was a stack-heeled step too far – until now
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45,000: SThree: SThree Group have been well e...

Ashdown Group: IT Manager / Development Manager - NW London - £58k + 15% bonus

£50000 - £667000 per annum + excellent benefits : Ashdown Group: IT Manager / ...

Recruitment Genius: Sales Consultant / Telemarketer - OTE £20,000

£13000 - £20000 per annum: Recruitment Genius: Scotland's leading life insuran...

Ashdown Group: Training Programme Manager - City, London

£40000 - £45000 per annum + benefits : Ashdown Group: Training Programme Manag...

Day In a Page

NHS struggling to monitor the safety and efficacy of its services outsourced to private providers

Who's monitoring the outsourced NHS services?

A report finds that private firms are not being properly assessed for their quality of care
Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

The Tory MP said he did not want to stand again unless his party's manifesto ruled out a third runway. But he's doing so. Watch this space
How do Greek voters feel about Syriza's backtracking on its anti-austerity pledge?

How do Greeks feel about Syriza?

Five voters from different backgrounds tell us what they expect from Syriza's charismatic leader Alexis Tsipras
From Iraq to Libya and Syria: The wars that come back to haunt us

The wars that come back to haunt us

David Cameron should not escape blame for his role in conflicts that are still raging, argues Patrick Cockburn
Sam Baker and Lauren Laverne: Too busy to surf? Head to The Pool

Too busy to surf? Head to The Pool

A new website is trying to declutter the internet to help busy women. Holly Williams meets the founders
Heston Blumenthal to cook up a spice odyssey for British astronaut manning the International Space Station

UK's Major Tum to blast off on a spice odyssey

Nothing but the best for British astronaut as chef Heston Blumenthal cooks up his rations
John Harrison's 'longitude' clock sets new record - 300 years on

‘Longitude’ clock sets new record - 300 years on

Greenwich horologists celebrate as it keeps to within a second of real time over a 100-day test
Fears in the US of being outgunned in the vital propaganda wars by Russia, China - and even Isis - have prompted a rethink on overseas broadcasters

Let the propaganda wars begin - again

'Accurate, objective, comprehensive': that was Voice of America's creed, but now its masters want it to promote US policy, reports Rupert Cornwell
Why Japan's incredible long-distance runners will never win the London Marathon

Japan's incredible long-distance runners

Every year, Japanese long-distance runners post some of the world's fastest times – yet, come next weekend, not a single elite competitor from the country will be at the London Marathon
Why does Tom Drury remain the greatest writer you've never heard of?

Tom Drury: The quiet American

His debut was considered one of the finest novels of the past 50 years, and he is every bit the equal of his contemporaries, Jonathan Franzen, Dave Eggers and David Foster Wallace
You should judge a person by how they peel a potato

You should judge a person by how they peel a potato

Dave Hax's domestic tips are reminiscent of George Orwell's tea routine. The world might need revolution, but we like to sweat the small stuff, says DJ Taylor
Beige is back: The drab car colours of the 1970s are proving popular again

Beige to the future

Flares and flounce are back on catwalks but a revival in ’70s car paintjobs was a stack-heeled step too far – until now
Bill Granger recipes: Our chef's dishes highlight the delicate essence of fresh cheeses

Bill Granger cooks with fresh cheeses

More delicate on the palate, milder, fresh cheeses can also be kinder to the waistline
Aston Villa vs Liverpool: 'This FA Cup run has been wonderful,' says veteran Shay Given

Shay Given: 'This FA Cup run has been wonderful'

The Villa keeper has been overlooked for a long time and has unhappy memories of the national stadium – but he is savouring his chance to play at Wembley
Timeless drama of Championship race in league of its own - Michael Calvin

Michael Calvin's Last Word

Timeless drama of Championship race in league of its own